Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others

Dermavant Sciences announced that VTAMA® (tapinarof) cream, 1%, an aryl hydrocarbon receptor agonist, indicated for the topical treatment of plaque psoriasis in adults, has been approved by the U.S. Food and Drug Administration (FDA). VTAMA® cream provides efficacy over 52 weeks and is well-tolerated on the most sensitive skin areas. This approval makes VTAMA® cream the first and only FDA-approved non-steroid topical medication for adults living with plaque psoriasis. The product is expected to be available beginning June 2022.

Read Full Press Release 

Stay informed

Join the email list to receive the latest information on psoriasis meetings, manuscripts and research.

now available

COVID-19 Psoriasis Resource Center

Information from around the world on psoriasis and coronavirus to assist dermatologists and the patients they serve

explore now


on SARS-CoV-2 Vaccines and Psoriasis

Six key take-aways that physicians and other healthcare practitioners should consider when administering the SARS-CoV-2 vaccine to psoriasis patients.


We use cookies on this site to enhance your online experience. By continuing to use this site, you agree to accept cookies.